Fertility care specialist, Alpha IVF Group Berhad and its subsidiaries aim to raise RM466.5 million from its Initial Public Offering (IPO) on the ACE Market of Bursa Malaysia Securities Berhad.
The IPO exercise entails a total of 1,458.0 million ordinary shares in Alpha IVF priced at RM0.32 per share, comprising 364.5 million new shares and 1,093.5 million offer-for-sale shares from eight offerors.
During the IPO prospectus launch today, Alpha IVF Group Executive Director and Group Managing Director, Dato’ Dr. Colin Lee Soon Soo stated that the IPO marked the initiation of a new phase in the Group’s growth strategy. Of the targeted RM466.5 million IPO proceeds, RM116.6 million will be accrued to Alpha IVF Group, while the balance RM349.9 million will be accrued entirely to the offerors. Out of the total proceeds of RM116.6 million received by Alpha IVF Group, RM72.8 million will be allocated to establish new IVF centres, satellite clinics, and sales representative offices as part of their expansion plan domestically and internationally.
A further RM15.7 million will be allocated for expansion and upgrade of existing specialist centres, facilities, and corporate office; RM2.2 million for research and development (R&D), as well as the remaining RM25.9 million for general working capital, general corporate purposes, and defraying of listing expenses.
Dato’ Dr Colin Lee Soon Soo, Group Managing Director of Alpha IVF Group Berhad said “Through this IPO, we are looking to raise approximately RM116.6 million in total proceeds for Alpha IVF Group, which will help to support our capital expenditure and working capital requirements for future growth. The first pillar of our growth strategy is focused on domestic expansion, as we aim to establish three full-fledged fertility centres in Malaysia by the financial year ending 31 May 2026 (FYE 2026).
The IPO structure comprises an Institutional Offering of 1,239.3 million shares to institutional and selected investors, including 607.5 million shares allocated to Bumiputera investors approved by the Ministry of Investment, Trade, and Industry (Malaysia). Among the total institutional offering, 145.8 million are newly issued shares.
The remaining 218.7 million new shares constitute the Retail Offering, with 194.4 million shares available to the Malaysian public through balloting. Additionally, 24.3 million shares are allocated to eligible directors, employees, and individuals who have contributed to the success of Alpha IVF.
The group aims to distribute at least 60% of the annual audited profit after tax attributable to shareholders to reward the shareholders.
